Extracellular cyclic AMP-dependent protein kinase autoantibodies and C-reactive protein as serum biomarkers for diagnosis of cancer in dogs
OPEN Veterinary and comparative oncology | 10 Nov 2018
MO Ryu, BG Kim, US Choi, KH Baek, YK Song, Q Li, KW Seo, S Ryeom, HY Youn and DH Bhang
Protein kinase A, a cyclic AMP-dependent enzyme, normally exists within mammalian cells; however, in cancer cells, it can leak out and be found in the serum. Extracellular cyclic AMP-dependent protein kinase A (ECPKA) has been determined to increase in the serum of cancer-bearing dogs. However, there have been no reports in the veterinary literature on serum ECPKA autoantibody (ECPKA-Ab) expression in dogs with cancer. The aim of this study was to evaluate ECPKA-Ab and C-reactive protein (CRP) as serum biomarkers for cancer in dogs. ECPKA-Ab and CRP levels were detected by an enzyme-linked immunosorbent assay in serum samples from dogs with malignant tumors (n = 167), benign tumors (n = 42), or non-tumor disease (n = 155) and from healthy control dogs (n = 123). ECPKA-Ab and CRP levels were significantly higher in the dogs with malignant tumors than in those with benign tumors or non-tumor diseases, as well as in the healthy controls (p<0.001, Kruskal-Wallis test). There was a significant positive correlation between the neoplastic index, which was developed using ECPKA-Ab and CRP levels, and the presence of cancer in dogs (p<0.001); the area under the receiver operating characteristic curve was estimated to be >0.85 (p<0.001). In conclusion, ECPKA-Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA-Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs.
* Data courtesy of Altmetric.com